CurrentBlue Cross Blue Shield - IowaPolicy 05.05.42

Wegovy Cardiovascular Risk Reduction

Defines prior authorization, clinical criteria, documentation, prescriber specialty, dosing/quantity limits, and continuation requirements for Wegovy (semaglutide) injection and tablet for cardiovascular risk reduction in adults with established CVD and for Wegovy injection for metabolic dysfunction-associated steatohepatitis (MASH). Applies to members whose benefits include coverage for the drug.

Policy Summary

PayerBlue Cross Blue Shield - Iowa

PolicyWegovy Cardiovascular Risk Reduction

Policy CodePolicy 05.05.42

Change TypeRevised (Apr 2026)

Effective DateMay 15, 2026

Next Review Date

Key ActionSubmit prior authorization with chart notes/records supporting established CVD, current BMI within 90 days, and documentation of guideline-directed therapies; for MASH include one definitive diagnostic record (liver biopsy, FAST, MAST, or MEFIB).

SourceLink

POLICY UPDATE CHANGES

Policy reviewed and revised April 2026; current effective date May 15, 2026.

2Primary covered indications (CVD risk reduction, MASH)

>=27BMI threshold for CVD indication

4Max injection pens per 28 days

30Max tablets per 30 days

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Summary

This policy provides coverage for Wegovy (semaglutide) both as a weekly subcutaneous injection and as an oral tablet when the member meets specified clinical criteria consistent with FDA‑approved indications: risk reduction of major adverse cardiovascular events in adults with established cardiovascular disease and overweight/obesity (injection or tablet) and treatment of noncirrhotic metabolic dysfunction‑associated steatohepatitis (MASH) with moderate to advanced fibrosis (Wegovy injection). Coverage is contingent on meeting the policy's clinical criteria, submission of required documentation, and any applicable quantity/dosing limits.

Coverage is conditional on documentation requirements and program rules: prior authorization with supporting chart notes/records (e.g., evidence of established CVD, current BMI, guideline‑directed therapies for CVD, or definitive diagnostic testing for MASH), adherence to prescriber specialty requirements for initial requests, and adherence to stated quantity limits. The policy does not recommend coadministration with other semaglutide‑containing products or any other GLP‑1 receptor agonist, and requests will not be approved if the member will use Wegovy concurrently with another GLP‑1 receptor agonist or another targeted weight‑loss agent.

Quick facts / thresholds

BMI threshold>= 27 kg/m2

Ankle‑Brachial Index (PAD) threshold<0.85 at rest

Adherence required for continuation>= 80% fill rate (claims evidence)

Pancreatitis exclusion window>180 days (no pancreatitis ≤180 days prior to request)

Injection quantity limit4 pens per 28 days (all listed strengths)

Tablet quantity limit30 tablets per 30 days (listed strengths)

Initial Therapy Criteria — Cardiovascular Risk Reduction

Initial Approval - Cardiovascular Risk Reduction (Wegovy injection or tablet)

Member must meet ALL of the following criteria:

ALL of the following

ANY of the following
- Prior myocardial infarction
- Prior stroke
- ANY of the following
  - Intermittent claudication with ankle-brachial index <0.85 at restAnkle-Brachial Index <0.85 at rest

Initial Therapy Criteria — MASH

Initial Approval - MASH (Wegovy injection)

Member must meet ALL of the following criteria:

ALL of the following

Member is 18 years of age or olderAge >= 18
ALL of the following
- ONE of: Liver biopsy
- ONE of: FAST (FibroScan-aspartate aminotransferase (AST))

Continuation Therapy Criteria — Cardiovascular Risk Reduction

Continuation of Therapy - Cardiovascular Risk Reduction (Wegovy injection or tablet)

Member must meet ALL of the following criteria:

ALL of the following

ANY of the following
- Prior myocardial infarction
- Prior stroke
- ANY of the following
  - Intermittent claudication with ankle-brachial index <0.85 at restAnkle-Brachial Index <0.85 at rest

Continuation Therapy Criteria — MASH

Continuation of Therapy - MASH (Wegovy injection)

Member must meet ALL of the following criteria:

ALL of the following

Member has achieved or maintained a positive clinical response to the requested drug (e.g., improvement in liver function such as reduction in ALT, reduction of liver fat content by imaging such as MRI-PDFF or FibroScan CAP)
Examples of positive response: ALT reduction, MRI-PDFF, FibroScan CAP
ALL of the following
- Progression to cirrhosis
- Hepatic decompensation

Not Medically Necessary / Other

Provider Actions & Authorization Requirements

Prior Authorization

Prior authorization required with documentation

Prior authorization is required. Submit chart notes, medical records, or claims history supporting established cardiovascular disease (prior MI, prior stroke, or symptomatic peripheral arterial disease), current BMI documented within 90 days, and documentation of concomitant guideline-directed medical therapies (antiplatelet, lipid-lowering, antihypertensive). For MASH requests include one definitive diagnostic record such as liver biopsy, FAST, MAST, or MEFIB. For continuation of MASH therapy, include records demonstrating positive clinical response from baseline.

Chart notes, medical records, or claims history for established CVD (prior MI, prior stroke, or symptomatic PAD)
BMI measurement within 90 days
Documentation of concomitant guideline-directed therapies (antiplatelet, lipid-lowering, antihypertensive)
For MASH: one definitive diagnostic record (liver biopsy, FAST, MAST, or MEFIB)
For MASH continuation: medical records showing positive clinical response from baseline

Applicable Codes & Quantity Limits

Referenced billing codes (general instruction)mixed

No codes listed

Wegovy injection quantity limits (NDC implied)NDCCovered

0.25 mg/0.5 mL auto-injector	Standard Limit = 4 pens/auto-injectors per 28 days
0.5 mg/0.5 mL auto-injector	Standard Limit = 4 pens/auto-injectors per 28 days
1 mg/0.5 mL auto-injector	Standard Limit = 4 pens/auto-injectors per 28 days
1.7 mg/0.75 mL auto-injector	Standard Limit = 4 pens/auto-injectors per 28 days
2.4 mg/0.75 mL auto-injector	Standard Limit = 4 pens/auto-injectors per 28 days

Wegovy tablet quantity limitsNDCCovered

1.5 mg tablet	Standard Limit = 30 tablets per 30 days
4 mg tablet	Standard Limit = 30 tablets per 30 days
9 mg tablet	Standard Limit = 30 tablets per 30 days
25 mg tablet	Standard Limit = 30 tablets per 30 days

Clinical Evidence

Key supporting evidence cited in the policy includes: LINCOFF et al., NEJM 2023 — the cardiovascular outcomes trial of semaglutide in people with obesity without diabetes supporting the cardiovascular risk‑reduction indication; Sanyal et al., NEJM 2025 — the phase 3 trial of semaglutide in MASH supporting the MASH indication; and the Wegovy [package insert], March 2026, which provides FDA‑approved indications, dosing, and limitations of use.

The package insert and policy language explicitly state that coadministration with other semaglutide‑containing products or any other GLP‑1 receptor agonist is not recommended and that approvals may be subject to dosing and quantity limits consistent with FDA labeling (e.g., injection pen and tablet standard limits and dosing escalation schedules).

Background & Definitions

Background: The policy aligns coverage with FDA‑approved indications for Wegovy injection and tablet for cardiovascular event risk reduction and with Wegovy injection for MASH, applying the FDA labeling and evidence base to define covered uses and required documentation.

The policy recommends against coadministration of Wegovy with other semaglutide‑containing products or any other GLP‑1 receptor agonist, and explicitly states that requests will not be approved if the member will be using the requested medication in combination with another GLP‑1 receptor agonist or another targeted weight‑loss agent. Coverage is contingent on meeting the clinical criteria and providing the required documentation (e.g., evidence of established CVD, current BMI within 90 days, documentation of guideline‑directed therapies for CVD, or one definitive diagnostic record for MASH) as described in the policy.

Definitions

MASH (term)Metabolic dysfunction-associated steatohepatitis (formerly NASH)

CVD (term)Established cardiovascular disease: prior MI, prior stroke, or symptomatic peripheral arterial disease as defined (e.g., intermittent claudication with ABI <0.85, peripheral arterial revascularization, or amputation due to ASCVD)

FAST / MAST / MEFIB (term)Noninvasive composite tests for MASH/fibrosis assessment: FAST (FibroScan + AST), MAST (MRI‑PDFF + MRE + AST), MEFIB (MRE + FIB‑4)

Revision History

2026-05-15effective_date

Policy current effective date set to May 15, 2026 per policy history.

2026-04reviewed_revisedLatest

Policy reviewed and revised April 2026 (non-material). Revision references the March 2026 Wegovy package insert and prior pivotal trials (LINCOFF et al. NEJM 2023; Sanyal et al. NEJM 2025).

Policy Summary

PayerBlue Cross Blue Shield - Iowa

PolicyWegovy Cardiovascular Risk Reduction

Policy CodePolicy 05.05.42

Change TypeRevised (Apr 2026)

Effective DateMay 15, 2026

Next Review Date

SourceLink

On This Page

Peripheral arterial revascularization procedure

Amputation due to atherosclerotic cardiovascular disease (ASCVD)

Body mass index (BMI) greater than or equal to 27 kg/m2BMI >= 27 kg/m2

ALL of the following

Diagnosis of diabetes mellitus (Hgb A1c of 6.5% or higher)Hgb A1c <6.5% to meet exclusion
Pancreatitis ≤180 days prior to requestNo pancreatitis within 180 days (i.e., >180 days since pancreatitis)

ALL of the following

Antiplatelet (e.g., aspirin, P2Y12 receptor blockers)
Lipid-lowering (e.g., statin, ezetimibe, PCSK9 inhibitors)
Antihypertensive (e.g., beta-blocker, ACE inhibitor OR ARB)

OR: Member has an inadequate response, intolerance, documented contraindication, or medically justifiable reason to preclude use of all medications in any or all of the above therapeutic classes

Member will continue the above therapies for secondary prevention of CVD in combination with the requested medication

Member is currently on and will continue a weight loss regimen of a reduced calorie diet and increased physical activity

FDA-indicated use in combination with reduced calorie diet and increased physical activity

Member will NOT be using the requested medication in combination with another targeted weight loss agent

Coadministration with other semaglutide-containing products or any other GLP-1 is not recommended

ONE of: MAST (derived from MRI-PDFF, MRE, and AST)

ONE of: MEFIB (MRE combined with fibrosis-4 index (FIB-4))

ALL of the following

Cirrhosis
Hepatic decompensation
Hepatocellular carcinoma (HCC)

Member will not be using the requested medication in combination with another GLP-1 receptor agonist

Coadministration with other GLP-1 receptor agonists is not recommended

Requested medication will be used in conjunction with healthy lifestyle modifications (e.g., dietary or caloric restriction, exercise, behavioral support, community-based program)

Peripheral arterial revascularization procedure

Amputation due to atherosclerotic cardiovascular disease (ASCVD)

Body mass index (BMI) greater than or equal to 27 kg/m2BMI >= 27 kg/m2

Member is adherent to therapy as evidenced by claims records demonstrating ≥80% fill rateAdherence >= 80% fill rate

Member has not developed type 2 diabetes mellitus

Diabetes exclusion maintained

ALL of the following

Antiplatelet (e.g., aspirin, P2Y12 receptor blockers)
Lipid-lowering (e.g., statin, ezetimibe, PCSK9 inhibitors)
Antihypertensive (e.g., beta-blocker, ACE inhibitor OR ARB)

OR: Member has an inadequate response, intolerance, documented contraindication, or medically justifiable reason to preclude use of all medications in any or all of the above therapeutic classes

Member is not experiencing unacceptable side effects or toxicities (i.e., pancreatitis)No unacceptable toxicities

Pancreatitis exclusion window applies

Requested medication will not be used in combination with another targeted weight loss agent

Coadministration with other semaglutide-containing products or GLP-1s is not recommended

Documentation Required

Continuation evidence requirement

For continuation requests, provide evidence of adherence and clinical benefit. Specifically: documentation of adherence from claims/dispensing records demonstrating a ≥80% fill rate; documentation of clinical benefit (for MASH, examples include improvement in ALT, reduction in liver fat by MRI-PDFF, or improved FibroScan CAP); and documentation that the member has not progressed to cirrhosis or hepatic decompensation and is not experiencing unacceptable toxicities (e.g., pancreatitis).

Claims/dispensing records showing ≥80% fill rate
Clinical benefit measures (for MASH: reduction in ALT, MRI-PDFF, or FibroScan CAP)
No progression to cirrhosis, hepatic decompensation, or development of unacceptable toxicities (e.g., pancreatitis)

Hepatocellular carcinoma (HCC)

Member will not be using the requested medication in combination with another GLP-1 receptor agonist

Coadministration with other GLP-1 receptor agonists is not recommended

Requested medication will be used in conjunction with healthy lifestyle modifications (e.g., dietary or caloric restriction, exercise, behavioral support, community-based program)

Documentation Required

Prescriber specialty requirement

Initial requests must be prescribed by or in consultation with specified specialists. For cardiovascular risk reduction: Cardiologist, Endocrinologist, Lipid specialist, Cardiometabolic specialist, or Primary care physician in consultation with one of these specialists. For MASH: Gastroenterologist, Hepatologist, Cardiometabolic specialist, or Primary care physician in consultation with one of these specialists.

CVD initial prescribers: Cardiologist; Endocrinologist; Lipid specialist; Cardiometabolic specialist; PCP in consultation with above
MASH initial prescribers: Gastroenterologist; Hepatologist; Cardiometabolic specialist; PCP in consultation with above

Billing Rule

Quantity limits

Quantity limits apply per formulation. Injection auto-injector pens: standard limit = 4 pens per 28 days (for all listed strengths). Tablets: standard limit = 30 tablets per 30 days (for all listed strengths). Approvals may be subject to dosing limits per FDA labeling.

Injection pens: 4 pens / 28 days (all listed strengths)
Tablets: 30 tablets / 30 days (all listed strengths)
Approvals subject to FDA dosing limits and labeling

Denial Risk

Denial risk for concurrent GLP-1 or targeted weight loss agent

Requests will not be approved if the member will use the requested medication in combination with another GLP-1 receptor agonist or another targeted weight-loss agent. Coadministration with other semaglutide-containing products or any other GLP-1 receptor agonist is not recommended.

Do not combine with other GLP-1 receptor agonists or semaglutide-containing products
Do not use concurrently with another targeted weight-loss agent

Documentation Required

Continuation evidence

For continuation, submit: claims or dispensing records demonstrating adherence (≥80% fill rate); clinical benefit documentation (for MASH: improvement in ALT, reduction in liver fat by MRI-PDFF, or improved FibroScan CAP); and documentation that the member has not progressed to cirrhosis or hepatic decompensation and is not experiencing unacceptable adverse effects (e.g., pancreatitis).

Adherence evidence: ≥80% fill rate from claims/dispensing records
Clinical benefit: for MASH, reduction in ALT or liver fat by MRI-PDFF or FibroScan CAP
No progression to cirrhosis or hepatic decompensation and no unacceptable toxicities (e.g., pancreatitis)